Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies

References

• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
   PubMed Web of Science ®Google Scholar
• Fischer N, Leger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14; PMID:17496428; http://dx.doi.org/10.1159/000101046
   PubMed Web of Science ®Google Scholar
• Boersma YL, Chao G, Steiner D, Wittrup KD, Pluckthun A. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem 2011; 286:41273-85; PMID:21979953; http://dx.doi.org/10.1074/jbc.M111.293266
   PubMed Web of Science ®Google Scholar
• Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, Yamniuk AP, Hosbach J, Brown J, Fitzpatrick E, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3:38-48; PMID:21099371; http://dx.doi.org/10.4161/mabs.3.1.14168
   PubMed Web of Science ®Google Scholar
• Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15:159-63; PMID:9035142; http://dx.doi.org/10.1038/nbt0297-159
   PubMed Web of Science ®Google Scholar
• Demarest SJ, Glaser S. M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008; 11:675-87; PMID:18729019
   PubMed Web of Science ®Google Scholar
• Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393:672-792; PMID:19699208; http://dx.doi.org/10.1016/j.jmb.2009.08.032
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:4703-17; PMID:21123183; http://dx.doi.org/10.1074/jbc.M110.184317
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009; 1:128-41; PMID:20061822; http://dx.doi.org/10.4161/mabs.1.2.7631
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
   PubMed Web of Science ®Google Scholar
• Rothlisberger D, Honegger A, Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347:773-89; PMID:15769469; http://dx.doi.org/10.1016/j.jmb.2005.01.053
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
   PubMed Web of Science ®Google Scholar
• Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
   PubMed Web of Science ®Google Scholar
• Richman SA, Aggen DH, Dossett ML, Donermeyer DL, Allen PM, Greenberg PD, Kranz DM. Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Mol Immunol 2009; 46:902-16; PMID:18962897; http://dx.doi.org/10.1016/j.molimm.2008.09.021
   PubMed Web of Science ®Google Scholar
• Brocker T, Karjalainen K. Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors. Adv Immunol 1998; 68:257-69; PMID:9505091; http://dx.doi.org/10.1016/S0065-2776(08)60561-1
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
   PubMed Web of Science ®Google Scholar
• Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987; 149:960-8; PMID:3122749; http://dx.doi.org/10.1016/0006-291X(87)90502-X
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989; 86:10024-8; PMID:2513569; http://dx.doi.org/10.1073/pnas.86.24.10024
   PubMed Web of Science ®Google Scholar
• Brocker T, Riedinger M, Karjalainen K. Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. Eur J Immunol 1996; 26:1770-4; PMID:8765019; http://dx.doi.org/10.1002/eji.1830260816
   PubMed Web of Science ®Google Scholar
• Brocker T, Peter A, Traunecker A, Karjalainen K. New simplified molecular design for functional T cell receptor. Eur J Immunol 1993; 23:1435-9; PMID:8325320; http://dx.doi.org/10.1002/eji.1830230705
   PubMed Web of Science ®Google Scholar
• Traunecker A, Dolder B, Karjalainen K. A novel approach for preparing anti-T cell receptor constant region antibodies. Eur J Immunol 1986; 16:851-4; PMID:3087759; http://dx.doi.org/10.1002/eji.1830160722
   PubMed Web of Science ®Google Scholar
• Seimiya H, Naito M, Mashima T, Yasui H, Kuwana Y, Kurosawa Y, Tsuruo T. T cell receptor-extracellular constant regions as hetero-cross-linkers for immunoglobulin variable regions. J Biochem 1993; 113:687-91; PMID:8370665
   PubMed Web of Science ®Google Scholar
• Feige MJ, Groscurth S, Marcinowski M, Shimizu Y, Kessler H, Hendershot LM, Buchner J. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell 2009; 34:569-79; PMID:19524537; http://dx.doi.org/10.1016/j.molcel.2009.04.028
   PubMed Web of Science ®Google Scholar
• Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64:2343-6; PMID:15059883; http://dx.doi.org/10.1158/0008-5472.CAN-03-3856
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10.1038/nature01392
   PubMed Web of Science ®Google Scholar
• Demarest SJ, Hopp J, Chung J, Hathaway K, Mertsching E, Cao X, George J, Miatkowski K, LaBarre MJ, Shields M, et al. An intermediate pH unfolding transition abrogates the ability of IgE to interact with its high affinity receptor FcepsilonRIalpha. J Biol Chem 2006; 281:30755-67; PMID:16905745; http://dx.doi.org/10.1074/jbc.M605190200
   PubMed Web of Science ®Google Scholar
• Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, Strong R, Theobald M, Greenberg PD. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med 2009; 206:463-75; PMID:19171765; http://dx.doi.org/10.1084/jem.20082487
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Ramakrishnan C, Balaram P. Beta-hairpins in proteins revisited: lessons for de novo design. Protein Eng 1997; 10:1131-41; PMID:9488138; http://dx.doi.org/10.1093/protein/10.10.1131
   PubMedGoogle Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535-6108(04)00083-2
   PubMed Web of Science ®Google Scholar
• Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 2008; 13:365-73; PMID:18394559; http://dx.doi.org/10.1016/j.ccr.2008.02.019
   PubMed Web of Science ®Google Scholar
• Sethuraman N, Stadheim TA. Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 2006; 17:341-6; PMID:16828275; http://dx.doi.org/10.1016/j.copbio.2006.06.010
   PubMed Web of Science ®Google Scholar
• Lepenies B, Lee J, Sonkaria S. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev 2013; 65:1271-81; PMID:23727341; http://dx.doi.org/10.1016/j.addr.2013.05.007
   PubMed Web of Science ®Google Scholar
• Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M, Hsu YM, Whitty A. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005; 44:1919-31; PMID:15697217; http://dx.doi.org/10.1021/bi048227k
   PubMed Web of Science ®Google Scholar
• Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007; 355:751-7; PMID:17321501; http://dx.doi.org/10.1016/j.bbrc.2007.02.042
   PubMed Web of Science ®Google Scholar
• Scheer JM, Sandoval W, Elliott JM, Shao L, Luis E, Lewin-Koh SC, Schaefer G, Vandlen R. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PLoS One 2012; 7:e51817; PMID:23284778; http://dx.doi.org/10.1371/journal.pone.0051817
   PubMed Web of Science ®Google Scholar
• Jost C, Pluckthun A. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Curr Opin Struct Biol 2014; 27:102-12; PMID:25033247; http://dx.doi.org/10.1016/j.sbi.2014.05.011
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Wright PE, Dyson HJ. PCR-based gene synthesis and protein NMR spectroscopy. Structure 1997; 5:1407-12; PMID:9384559; http://dx.doi.org/10.1016/S0969-2126(97)00291-8
   PubMed Web of Science ®Google Scholar
• Cooper CA, Gasteiger E, Packer NH. GlycoMod–a software tool for determining glycosylation compositions from mass spectrometric data. Proteomics 2001; 1:340-9; PMID:11680880; http://dx.doi.org/10.1002/1615-9861(200102)1:2<340::AID-PROT340>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar